

**Panacea Biotec reports financial results
for the Quarter & Half Year ended September 30, 2009**

New Delhi, October 29, 2009: Panacea Biotec today announced its unaudited financial results for the quarter and half year ended September 30, 2009. The Company's Board met here on Thursday, October 29, 2009 to consider and approve its unaudited financial results for the quarter and half year ended September 30, 2009. The results were also reviewed by the Company's Audit committee in their meeting held on Wednesday, October 28, 2009 and subjected to limited review by the Company's statutory auditors.

Quarter ended September 30, 2009: The Company's net turnover grew by 14% and stands at Rs. 1,658 million during the quarter ended September 30, 2009 as compared to Rs. 1,454 million for the corresponding period of previous financial year. The Formulations turnover grew by 17% in domestic pharma market, registered segment turnover of Rs. 605 million as compared to Rs. 554 million during the corresponding quarter of previous financial year. The vaccine segment grew by 17% and registered turnover of Rs. 1,053 million as against Rs. 899 million during corresponding quarter of previous financial year. The Company reported 109% growth in its PBT at Rs. 30 million as compared to negative PBT of Rs. 323 million during the corresponding quarter of previous financial year.

Half year ended September 30, 2009: During the half year ended September 30, 2009, the company registered net turnover of Rs. 3,430 million as compared to Rs. 3,699 million for the corresponding period of previous financial year. The Formulations segment registered turnover of Rs. 1,178 million as compared to Rs. 1,207 million during the corresponding period of previous financial year. The vaccine segment registered turnover of Rs. 2,252 million as against Rs. 2,490 million during corresponding quarter of previous financial year. The Company reported 68% growth in its PBT at Rs. 241 million as compared to Rs. 144 million during the corresponding quarter of previous financial year.

Dr. Rajesh Jain, Joint Managing Director said, "In the current quarter our strategic focus on domestic pharma has resulted into growth of 17% much higher than industry growth of 12%. As a major contributor to revenues, vaccines segment has maintained a growth of 17% in the quarter. We are optimistic of the overall earnings for the year expected to be pushed up by the recent order for EasyFiveTM worth USD 222.37 million (over Rs. 1,067 crore)."

In august this year, Panacea Biotec received Award Notification for supply of its EasyFive (pentavalent vaccine), from UNICEF for years 2010, 2011 and 2012. The Company received the pre-qualification for EasyFive by WHO in July last year. Pentavalent vaccines are used by UN agencies (UNICEF, PAHO etc.) to vaccinate and save precious lives of millions of children in the developing world. EasyFive offers a befitting solution to overcome complexity of childhood vaccination program.



Dr. Rajesh Jain further added “Panacea Biotec is one of the three Indian companies closely working with Indian Council of Medical Research and DCGI to develop an indigenous vaccine against H1N1 flu (PandyFlu) in an accelerated manner. We plan to make the H1N1 (PandyFlu) vaccine available by April 2010.”

“We expect considerably better performance in the second half of FY2010 owing to the EasyFive order along with the Oral Polio Vaccines sales yielding results in Q4.

About Panacea Biotec

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey- June 2009) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. Panacea Biotec has five dedicated research and development centers. The company has around 3200 employees including over 300 scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

For further details please contact:

Veenu Kapoor

Deputy Manager - Corporate Communications

Mobile: 0 9 8 1 8 4 0 1 1 1 6

Land Line: 011-41679000; Fax: 011-41679096

Email: veenukapoor@panaceabiotec.com Website: www.panaceabiotec.com

Disclaimer

Except for the historical information contained herein, statements in this Release which contain words or phrases such as 'will', 'would', 'indicating', 'expected to' etc., and similar expressions or variations of such expressions may constitute 'forward-looking statements'. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, future business plans, our growth and expansion in business, the impact of any acquisitions, our financial capabilities, technological implementation and changes, the actual growth in demand for our products and services, cash flow projections, our exposure to market risks as well as other general risks applicable to the business or industry. Panacea Biotec undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date thereof.